An expert panel has advised the Food and Drug Administration not to approve a new drug for attention deficit hyperactivity disorder. Panel members say the drug isn't safe enough to give to millions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback